74%
jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti.
74%
jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse.
Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
74%
jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti.
74%
jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse.
Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Bayer AG
Suletud
SektorRahandus
28.3 0.27
Ülevaade
Aktsiahinna muutus
24h
Min
27.665
Max
28.325
Sissetulek | -1.5B -190M |
|---|---|
Müük | -3B 11B |
P/E Sektori keskmine | 30.9 27.32 |
Aktsiakasum | 1.23 |
Dividenditootlus | 0.39 |
Kasumimarginaal | -1.769 |
Töötajad | 89,556 |
EBITDA | -3.4B 236M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | -0.28% downside |
Dividenditootlus Sektori keskmine | 0.39% 3.64% |
|---|---|
Järgmine tulemuste avaldamine | 11. nov 2025 |
Turukapital | 359M 27B |
|---|---|
Eelmine avamishind | 28.03 |
Eelmine sulgemishind | 28.3 |
Uudiste sentiment
By Acuity
29%
71%
110 / 531 Pingereas Finance
Tehniline skoor
By Trading Central
Kindlus
Bearish Evidence
Bayer AG Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Bayer AG Prognoos
Hinnasiht
By TipRanks
-0.28% langus
12 kuu keskmine prognoos
Keskmine 28.08 EUR -0.28%
Kõrge 35 EUR
Madal 23 EUR
Põhineb 13 Wall Streeti analüütiku instrumendi Bayer AG 12 kuu hinnasihil - viimase 3 kuu andmed.
Sentiment
By Acuity
110 / 531 Pingereas Rahandus
Uudiste sentiment
Languse märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Bayer AG
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.
Live chat